Register Login

Adicet Bio Inc (ACET)

(30% Negative) Adicet Bio, Inc. (ACET) Announces Delay in data Trials for October from our prula-cel P Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 7, 2026, 1:35 p.m.

    📋 Adicet Bio, Inc. (ACET) - Clinical Trial Update

    Filing Date: 2026-01-07

    Accepted: 2026-01-07 08:30:12

    Event Type: Clinical Trial Update

    Event Details:

    Adicet Bio Inc (ACET) Announces Clinical Trial Update Adicet Bio Inc (ACET) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: data
    • Diseases/Conditions: October from our prula-cel P
    • Clinical Stage: Phase 1 study, Phase 1 trial
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: SLE
      • expected in 1H/2026
      • expected in the first half of 2026

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Adicet Bio Inc
    • CIK: 0001720580
    • Ticker Symbol: ACET
    • Period End Date: 2026-01-07
    • Document Type: 8-K

Search

News categories